Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26,258 result(s) found for: NA. Displaying page 976 of 1,313.
    «« First « Previous 972  973  974  975  976  977  978  979  980  Next» Last»»
    EudraCT Number: 2021-002331-34 Sponsor Protocol Number: ALOFEC-2019 Start Date*: 2022-11-08
    Sponsor Name:FIMABIS
    Full Title: A multicenter, randomized, double-blind Phase IIb study to evaluate the safety and efficacy of the intralesional administration of two doses of expanded allogeneic adipose tissue adult stem mesench...
    Medical condition: Fecal incontinence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10016296 Fecal incontinence LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003599-39 Sponsor Protocol Number: SAKK08/15 Start Date*: 2017-12-13
    Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK)
    Full Title: PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy
    Medical condition: Histologically confirmed adenocarcinoma of the prostate without small cell features with PSA progression after radical prostatectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002540-25 Sponsor Protocol Number: CSTI571A2406 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued ima...
    Medical condition: Male and female patients who are currently enrolled in a Novartis-sponsored, Oncology OGD&GMA imatinib study, are benefiting from treatment with imatinib and have fulfilled all their requirements ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001670-33 Sponsor Protocol Number: 215344 Start Date*: 2022-02-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
    Medical condition: Healthy volunteers (Active immunization against IMD caused by N.meningitidis serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004742-23 Sponsor Protocol Number: CRTH258B2301 Start Date*: 2018-09-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to D...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000254-21 Sponsor Protocol Number: MO39839 Start Date*: 2021-04-20
    Sponsor Name:University Hospital Essen
    Full Title: Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) in local head and neck squamous cell carcinoma
    Medical condition: local squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002428-10 Sponsor Protocol Number: KTxSGLT2i-22 Start Date*: 2023-03-06
    Sponsor Name:Oslo Univeristy Hospital - Rikshospitalet
    Full Title: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS?
    Medical condition: Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and va...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006638-38 Sponsor Protocol Number: 2021/3282 Start Date*: 2022-05-18
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)
    Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000891-20 Sponsor Protocol Number: CA-4948-101 Start Date*: 2023-02-03
    Sponsor Name:Curis, Inc.
    Full Title: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or ...
    Medical condition: Relapsed or Refractory Hematologic Malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004630-42 Sponsor Protocol Number: TAS-120-301 Start Date*: 2021-01-25
    Sponsor Name:Taiho Oncology Inc
    Full Title: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangem...
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) DE (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002511-34 Sponsor Protocol Number: V1.0.14062017 Start Date*: 2018-09-26
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial)
    Medical condition: Chronic inflammatory demyelinating polyneuropathy (CIDP)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021715-17 Sponsor Protocol Number: 1220.7 Start Date*: 2011-07-12
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot...
    Medical condition: Chronic hepatitis C infection genotype 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000191-21 Sponsor Protocol Number: M14-496 Start Date*: 2017-01-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 4 open-label randomized controlled study COmparing the effectiveness of adalimumab iNTROduction and methotrexate dose escaLation in subjects with Psoriatic Arthritis (CONTROL)
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GB (Completed) PL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008005-21 Sponsor Protocol Number: DIM18 Start Date*: 2009-07-28
    Sponsor Name:Medivation, Inc.
    Full Title: CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donep...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) FI (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002683-14 Sponsor Protocol Number: DSE-EDO-01-15-EU Start Date*: 2017-01-12
    Sponsor Name:Daiichi Sankyo Europe GmbH
    Full Title: Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent p...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GB (Completed) NL (Completed) DE (Completed) LT (Completed) ES (Completed) AT (Completed) HU (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001234-20 Sponsor Protocol Number: LOXO-BTK-20023 Start Date*: 2021-10-21
    Sponsor Name:LOXO ONCOLOGY INCORPORATED
    Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Completed) FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005394-37 Sponsor Protocol Number: C31004 Start Date*: 2016-08-31
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced...
    Medical condition: Advanced, Recurrent, or Persistent Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10014735 Endometrial cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 972  973  974  975  976  977  978  979  980  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 06:21:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA